Multiple sclerosis is a disease characterized by remissions and exacerbations of symptoms. Thus, any considerations of therapeutic influences on the symptomatology must be subjected to critical analysis because of the natural fluctuations in the course of the disease. Recently isoniazid was reported as favorably influencing multiple sclerosis. In their preliminary report, Kurtzke and Berlin1 did not claim unequivocal effectiveness of isoniazid but suggested that their results warranted further investigation. Their patients were, in the main, persons who had recent exacerbations of rather short duration.
This communication presents the results of the use of isoniazid in patients with multiple sclerosis of long standing. It was felt that a study of the effect of the drug on patients with persistent disabling features of the disease would be of special value for the evaluation of its therapeutic efficacy. In addition, a group of patients with other neurological disorders was selected for the
L. P. HINTERBUCHNER, M. G. GOLDNER, J. B. ROGOFF, A. M. RABINER. Effect of Isoniazid in Multiple Sclerosis with Chronic Symptomatology. AMA Arch NeurPsych. 1956;75(2):115–121. doi:10.1001/archneurpsyc.1956.02330200009001